Physician profile
Joseph G Christenbury
NPI 1679816458
$31,068.57
in general payments reported to CMS, 2019-2025
34 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what 86% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,184 · 2020: $2,745 · 2021: $5,550 · 2022: $7,105 · 2023: $8,836 · 2024: $1,254 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,500 · Food and Beverage: $5,846 · Education: $99.99 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,500.00 |
| Food and Beverage | $5,845.59 |
| Education | $99.99 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $13,971.68 | 2019-2025 | |
| Dompe US, INC. | $5,088.31 | 2019-2025 | Oxervate |
| Glaukos Corporation | $2,982.98 | 2020-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Johnson & Johnson Surgical Vision, INC. | $2,482.73 | 2019-2025 | Tecnis Iol, Veritas Vision System, Tecnis Simplicity |
| Alcon Vision LLC | $1,662.00 | 2019-2025 | Clareon, Unity, Centurion |
| Novartis Pharmaceuticals Corporation | $611.02 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $586.89 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $455.10 | 2022-2025 | Tyrvaya |
| Abbvie INC. | $397.39 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Rxsight INC | $388.72 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $299.79 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Mallinckrodt Hospital Products INC. | $297.20 | 2020-2025 | Acthar |
| Carl Zeiss Meditec USA, INC. | $266.87 | 2023-2025 | Quatera 700, Lumera 700, Artevo 800 |
| Sight Sciences, INC. | $244.88 | 2020-2022 | |
| Allergan, INC. | $220.13 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $191.40 | 2024-2025 | Vevye, Iheezo, Triesence |
| Carl Zeiss Meditec, INC. | $189.04 | 2022 | |
| Mallinckrodt Enterprises LLC | $155.24 | 2019 | |
| Thea Pharma INC. | $115.49 | 2023 | |
| Kala Pharmaceuticals, INC. | $105.47 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $85.18 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.65 | 2019-2021 | |
| Heidelberg Engineering, INC. | $31.99 | 2023 | Spectralis |
| Baxter Healthcare | $24.24 | 2022 | |
| Eyevance Pharmaceuticals LLC | $24.05 | 2019-2020 | |
| Lensar, INC. | $23.01 | 2024 | Lensar Laser System |
| Eyepoint US, INC. | $20.84 | 2019 | |
| Ivantis, INC | $15.51 | 2021 | |
| Lumenis, INC | $15.32 | 2021 | |
| Ocular Therapeutix, INC. | $14.96 | 2024 | Dextenza |
| Horizon Therapeutics Plc | $13.82 | 2020 | |
| Iridex Corporation | $8.67 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Christenbury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.